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Over 80% of all emergency department (ED) visits result in discharge. Conversely, over 80% 
of ED patients with AHF are admitted to the hospital. Disappointingly, this practice persists 
despite 20 years of effort, with little reason to believe it will change.1 While some patients 
clearly benefit from hospitalization, up to 50% of ED patients with AHF may be discharged 
or placed in observation.2, 3 Importantly, nearly half of all patients hospitalized with AHF 
present with lower risk features, such as a blood pressure > 140mmHg and a BNP < 1000 
pg/mL, supporting the idea of a lower risk cohort embedded within the overall AHF 
population.4 However, this cohort has many associated comorbidities. More importantly, a 
significant proportion is likely to experience an adverse event at rates perceived by most 
emergency physicians as too high for ED discharge.5
Many other ED-based cardiovascular disease processes (evaluations for acute coronary 
syndrome or pulmonary embolism) have evolved from high rates of admission to timely and 
safe ED discharge. Decision making in AHF has not experienced a similar evolution. There 
are several possible explanations for this lack of progress and we highlight several. First, ED 
providers may believe hospitalization imparts a protective effect and changes the trajectory 
of patient’s outcomes. While decongestion is a cornerstone of hospital management, there is 
no AHF therapy that definitively improves outcomes.6 Second, lack of early and aggressive 
ED-based therapy in an effort to improve symptoms and facilitate ED discharge is all too 
common. While these two challenges could be overcome, the third and greatest challenge 
remains: without an externally validated tool to identify low-risk AHF patients for safe, 
early discharge, risk-averse emergency physicians will default towards hospital admission. 
No doubt, risk-stratification remains an unmet need.
There is good news however. Greater efforts toward ED AHF risk-stratification have yielded 
instruments with adequate, even excellent, discriminatory statistics. Yet such risk-rules 
either suffer from limitations or external factors limiting their applicability, including 
retrospective cohort methodology, lack of external validation, different national healthcare 
systems, and decision rule complexity. (Table).
While there are exceptions, one notable limitation is their inclusion of high-risk features that 
most emergency physicians would consider automatic exclusions for discharge. Specific 
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examples include significantly worse acute kidney injury (AKI) or high troponin values. 
Importantly, the inability to determine the additive value of the risk score when combined 
with provider-estimated risk is worth highlighting. Physicians commonly believe in their 
own ability to estimate risk; yet in AHF, we appear to send patients home who are more 
likely to die than those we admit,12 admit patients who have an uneventful and brief hospital 
stay, and remain surprised by the proportion (4%) who experience death within 30-days.13 
This also makes one consider the competing risk of death and non-fatal re-hospitalization. 
Which risk is more concerning? Should we consider the event with the higher financial 
penalty? Both are important, especially to patients. However, stratifying the risk for death is 
paramount.
In this edition of Circulation, Lee and colleagues externally tested their 7-day (EHMRG7 – 
Emergency Heart Failure Mortality Risk Grade) and 30-day (EHMRG30) risk score in 
nearly 2000 patients at 9 hospitals in Ontario, Canada.14 Compared to most prior risk-
stratification studies, the authors externally tested their original rule in a prospective manner, 
in a separate cohort of patients, simultaneously determined physician estimated risk, and 
performed comprehensive follow-up. This step is critical prior to an implementation study. 
Importantly, a waiver of informed consent facilitated enrollment along the entire spectrum of 
disease severity. Their patients were older (median 81 years), with 71% having a prior 
diagnosis of HF, and a fair proportion of CV and non-CV comorbidities. Of these patients, 
21% were discharged from the ED. Those patients discharged home had <1.5% 7-day and 
3.3% 30-day mortality. Within 7 days, 39 patients died (2%) and by day 30 this rose to 138 
patients (7%). Of the 138 deaths, only 17 occurred outside the hospital. They divided 
patients into 5 pre-specified risk categories: very-low, low, intermediate, high, and very high. 
Patients in the very-low or low-risk (518 patients) categories had 7-day and 30-day mortality 
rates of 0%. The discrimination for physician estimated risk (AUC=0.71) was improved 
(AUC=0.82) with use of the EHMRG7 model (AUC=0.81). The EHMRG30 had slightly 
lower (0.77) discrimination when compared to EHMRG7. Another important key finding is 
the over-estimation of 7-day and 30-day mortality at the low-end of the risk spectrum by 
providers, and an underestimation of mortality at the higher end.
From the ED standpoint, 0% mortality at 7 and 30 days in the low risk group is very 
reassuring. Emergency physicians’ overestimation of risk in these same patients highlights 
the need for an objective score. Still, it would be good to know what element of the risk-
score drove categorization. Dichotomizing certain variables – such as EMS transport (at 
times inappropriately utilized in the US) and troponin (how positive?) – may sway the risk 
rule. Using an online EHMRG calculator, it is possible to categorize patients with either a 
SBP of 80mmHg, a very high troponin value, or significantly worse acute kidney injury into 
the low-risk group. This brings the challenge of real-world applicability into the crosshairs; 
for the decision rule to be used, it must account for patients who clearly need admission, but 
are categorized by the risk-score as low-risk. Arguably, this is unfair to the decision rule and 
discounts the rigor by which this rule was developed. Further, it renders clinical judgment 
obsolete. Nevertheless, it highlights the need for an implementation study. The absence of 
high-risk features in EMHRG suggests a lower-risk patient, however, they still may not be 
eligible for discharge because of other complicating and competing conditions.
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This study advances our understanding of the EHMRG rule, and risk-stratification in 
general, but there are several limitations to consider. Nearly 30% of patients have no prior 
history of HF. Although management of de novo HF varies country by country, in the US, 
such patients generally warrant admission. The need for decongestion, identification and 
management of precipitants, as well as investigating underlying cardiac structure and 
function is challenging to accomplish outside of the hospital setting. Similarly, how well 
does the model discriminate when high-risk patients are excluded? A risk rule for discharge 
has less utility in patients with hypotension, who require non-invasive or invasive 
ventilation, have very high troponin values or severe acute kidney injury. Once all the 
appropriate reasons to admit are taken out, how then do we decide what to do? Data 
collection was not standardized, and this can introduce inconsistency and inaccuracies. The 
authors discuss the use of net reclassification index to suggest how the EHMRG rule could 
impact physician decision making. However, this may not be a completely accurate picture 
of the rule’s impact. While there is a clear need to identify lower-risk patients safe for ED 
discharge, provider decision making accounts for the possible success of outpatient 
management given the severity of both AHF and non-AHF symptoms. Finally, the standard 
work-up in the participating EDs did not routinely include the use of natriuretic peptides or 
an electrocardiogram. Natriuretic peptides have been found in other risk models to be an 
important variable in the risk-stratification model.7, 10
Are we any closer to the holy grail of safe ED discharge based on an AHF risk rule? The 
EHMRG rule uses readily available data to stratify patients into low and very-low risk 
categories. It has been derived and externally tested in large cohorts of patients. The next 
logical step is to incorporate natriuretic peptides into the rule and test the additive value of 
this rule alongside provider risk estimation in a large randomized trial that includes a 
population of patients across the spectrum of disease severity throughout the US and 
Canada.
However, establishing a risk-rule is just one component needed to change the current ED 
approach to disposition decision making.15 Early, aggressive treatment is also necessary so 
that patients experience adequate symptom relief. Waiting to provide treatment until after the 
work-up is complete, or not providing sufficient treatment introduces unnecessary delays, 
fails to provide sufficient symptom relief and could prevent ED discharge. Once 
appropriately treated and risk-stratified, a reliable mechanism for early outpatient follow-up 
is mandatory. Some ED patients with AHF will have an established patient-provider 
relationship where outpatient follow-up is easily facilitated. However, rapid outpatient 
access for all patients regardless of the time of ED discharge and previous provider 
relationship is crucial for success.
Over the next decade there are great opportunities to increase the proportion of ED patients 
with AHF who can be safely discharged home. While such needed progress is unlikely to 
match the state of disposition decision making in other cardiovascular processes in the ED 
such as chest pain, studies such as ACUTE are a necessary step in the right direction. Other 
AHF rules require similar external testing and implementation studies to determine their 
optimal role in the ED. Such continued advances will help drive further improvements in 
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early treatment and local support for rapid outpatient follow-up – necessary items to safely 
discharge a larger proportion of patients with AHF.
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Table.
Risk-Instruments to Identify Low Risk for ED Discharge
Year Sample
size
Country Variables Risk
stratification
goal
External
Validation
Clinical
Validation
Stiell et.al.7 Ottawa 
Heart Failure Risk 
Scale
2017 1100 Canada - History of stroke or TIA
- History of intubation for 
respiratory distress
- Heart rate on ED arrival 
>=110
- Room Air SaO2 <90% on 
EMS or ED arrival
- ECG has acute ischemic 
changes
- Urea >=12
- Serum CO2 >=35
- Troponin I or T elevated to 
MI level
- NTproBNP >=5000
- During Walk test, SaO2 
<90% on room air or usual O2, 
or HR >= 100 during 3-minute 
walk test, or too ill to walk
30-day serious 
adverse events
Yes Maybe: 
clinicians 
told not to 
solely base 
their 
decision on 
OHFRS
Miro et.al.8 MEESI 2018 4711 Spain - Barthel index at admission
- Systolic blood pressure
- Age
- NTproBNP
- Potassium
- Troponin
- NYHA at admission
- Respiratory rate
- Low output symptoms?
- Oxygen saturation
- Episode associated with 
ACS?
- Hypertrophy on ECG?
- Creatinine
30-day mortality Yes No
Lee et.al. EHMRG9 2018 1983 Canada - Age
- Arrival by ambulance
- Systolic blood pressure 
(triage)
- Heart rate (triage)
- Oxygen saturation (triage)
- Potassium
- Creatinine
- Troponin
- Active cancer
- Metolazone use prior to ED 
arrival
- ST depression on 12 lead (30-
day model)
7 and 30-day 
mortality
Yes No
Collins et.al. 10 
STRATIFY
2015 1033 US -Age
-BMI
-BNP
-Diastolic blood pressure
-BUN
-Sodium
-Respiratory Rate
-Oxygen Saturation
-Troponin
-Dialysis
-On supplemental oxygen
-On outpatient ACEI
-QRS duration
5 and 30-day 
hierarchical 
adverse events
No No
Auble et.al.11 Acute 
Heart Failure Index
2008 8384 US - Sex
- History of (h/o) MI
- h/o angina
- h/o PTCA
Death or serious 
medical 
complication 
before discharge. 
Yes No
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Year Sample
size
Country Variables Risk
stratification
goal
External
Validation
Clinical
Validation
- h/o diabetes
- h/o lung disease
- Heart rate
- Respiratory Rate
- Systolic Blood Pressure
- Temperature
- Sodium
- Potassium
- BUN
- Creatinine
- Glucose
- WBC count
- Arterial pH
- ECG findings: MI
- ECG findings: Ischemia
- CXR: pulmonary congestion
- CXR: pleural effusion
Secondary: 
Inpatient death 
alone and 30-day 
mortality alone
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